Study register · detail
No direction reported
GRADE
High
44 citations
Samplen = 1.475 Pat. (gepoolt)
ControlHealthy controls without substance use
DesignSystematische Review + Meta-Analyse
Key finding
Unlike with alcohol and opioids, no significant difference in striatal dopamine receptor availability was found in cannabis users.
Summary
Meta-analysis of in-vivo neuroimaging studies on the striatal dopamine system in users of alcohol, opioids and cannabis (n=723 substance users, 752 healthy controls). Cannabis users showed NO significant reduction in striatal D2/D3 receptor availability compared with controls — in contrast to alcohol (g=0,46) and opioid users (g=1,17). Too few cannabis studies available to evaluate dopamine transporter or synthesis capacity.
P
PopulationConsumers of alcohol, opioids or cannabis, n=723 total, compared with n=752 healthy controls
I
InterventionChronic consumption of sedating substances (alcohol, opioids, cannabis)
C
ControlHealthy controls without substance use
O
OutcomeSignificantly reduced striatal D2/D3 receptor availability with alcohol (g=0.46) and opioids (g=1.17); reduced dopamine transporter availability with opioids (g=1.55); no differences in cannabis users
Confidence in the evidence
High
The highest of four GRADE levels, the effect estimate is very reliable.
Quality profile
Sample size
—
Blinding
—
Effect size
—
Citations / year
★★★★★
Authors
Share
Abstract
Use of alcohol, cannabis and opioids is highly prevalent and is associated with global disease burden and high economic costs. The exact pathophysiology of abuse or addiction associated with these sedative substances is not completely understood, but previous research implicates the important role of the striatal dopamine system in the addiction process. Multiple studies investigated changes in the striatal dopamine systems of users of sedative substances, but currently these results are very heterogeneous. Therefore, we conducted a meta-analysis of in vivo neuroimaging studies investigating dopaminergic alterations in the striatum of users of alcohol, opioids or cannabis. Analyses for each substance were conducted separately for the availability of D2/D3 dopamine receptors, dopamine transporters and dopamine synthesis capacity. In total, 723 substance users and 752 healthy controls were included. The results indicated a significant lower striatal D2/D3 receptor availability in alcohol users compared to controls (g = 0.46) but no difference in dopamine transporter availability or dopamine synthesis capacity. Our analysis indicated that changes of dopamine receptors and transporters are moderated by the duration of abstinence. Comparing opioid users with controls revealed a significant lower D2/D3 receptor availability (g = 1.17) and a significantly lower transporter availability (g = 1.55) in opioid users. For cannabis users, there was no significant difference in receptor availability compared to controls and too few studies provided information on dopamine transporter availability or synthesis capacity. Our analysis provides strong evidence for a central role of the striatal dopamine system in use of alcohol or opioids. Further studies are needed to clarify the impact of the dopamine system in cannabis users.
The impediment to action advances action.